Novanta Inc (NOVT) Stock Price & Analysis
Novanta Inc (NOVT) fell 2.25% to USD 160.65 as of June 10, 2026 at 00:53 UTC, according to Nexqual real-time market data.
NOVT last closed at USD 164.34; the session ranged USD 150.1–166.08 on volume of 891,725 shares. Market capitalization is $5.72B, with a 52-week range of USD 98.27–171.85 (NMS). Source: Nexqual, June 10, 2026 at 00:53 UTC.
Key Statistics (as of June 10, 2026 at 00:53 UTC)
| Price | USD 160.65 |
|---|---|
| Change | ▼ 2.25% (down) |
| Previous Close | USD 164.34 |
| Open | USD 151.33 |
| Day Range | USD 150.1 – 166.08 |
| 52-Week Range | USD 98.27 – 171.85 |
| Volume | 891,725 shares |
| Market Cap | $5.72B |
| Exchange | NMS |
Technical Analysis (NOVT)
Nexqual's technical model rates NOVT "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:53 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.21 (neutral) |
| vs SMA50 | Above (USD 140.09) |
| MACD | 6.58 (positive) |
Analyst Ratings (NOVT)
Wall Street analysts rate NOVT "Strong Buy" based on 2 analysts, with a mean price target of USD 175 (range USD 170–180), per Nexqual as of June 10, 2026 at 00:53 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 175 |
| High Target | USD 180 |
| Low Target | USD 170 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (NOVT)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.83 |
| Revenue Estimate | $262.30M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.81 vs est 0.78 ▲ beat |
| 2025-12-31 | USD 0.91 vs est 0.88 ▲ beat |
| 2025-09-30 | USD 0.87 vs est 0.82 ▲ beat |
| 2025-06-30 | USD 0.76 vs est 0.73 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Financials & Fundamentals (NOVT)
| Total Revenue | $1.00B |
|---|---|
| Revenue Growth (YoY) | +10.40% |
| Gross Margin | +44.23% |
| Operating Margin | +11.70% |
| Profit Margin | +5.35% |
| ROE | +5.16% |
| Debt / Equity | 22.22 |
| Current Ratio | 3.56 |
| Total Cash | $388.80M |
| Total Debt | $291.34M |
| Free Cash Flow | $87.25M |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Financial Health Score (NOVT)
Nexqual rates Novanta Inc's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:53 UTC.
| Growth | Mixed — Revenue +3.3% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 12% |
| Balance Sheet | Strong — $389M cash vs $291M debt, net cash position |
| Cash Flow | Solid — FCF $87M, 9% margin |
| Efficiency | Mixed — ROE 5%, ROA 4.6% |
Ownership (NOVT)
| Insider Ownership | +0.77% |
|---|---|
| Institutional Ownership | +119.46% |
| Shares Outstanding | 35.61M |
| Float | 35.32M |
| Short % of Float | +13.76% |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Leadership (NOVT)
Novanta Inc is led by Matthijs Glastra (age 56), CEO & Chairman of the Board, per Nexqual as of June 10, 2026 at 00:53 UTC.
| CEO & Chairman of the Board | Matthijs Glastra (age 56) |
|---|---|
| Chief Financial Officer | Robert J. Buckley (age 51) |
| Co-Chief Operating Officer of Automation Enabling Technologies | Charles G. Ravetto (age 54) |
| Co-Chief Operating Officer of Medical Solutions | John Lesica (age 49) |
| Senior Vice President of Corporate Development | Nissia Sabri |
Major Backers & Investors (NOVT)
Notable institutional backers of Novanta Inc include Price (T.Rowe) Associates Inc, Allspring Global Investments Holdings, LLC, Conestoga Capital Advisors, LLC, according to Nexqual as of June 10, 2026 at 00:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 5.01% |
| Allspring Global Investments Holdings, LLC | 4.99% |
| Conestoga Capital Advisors, LLC | 4.07% |
| Wasatch Advisors LP | 2.8% |
| Geneva Capital Management LLC | 2.62% |
| Conestoga Funds-Conestoga Small Cap Fund | 1.99% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.56% |
| BlackRock | 18.84% |
| State Street | 3.76% |
| Geode Capital | 2.63% |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
From Novanta Inc's Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally.
- The company operates Automation Enabling Technologies and Medical Solutions segments.
- The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles.
- This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPSC | SPS Commerce, Inc. | USD 55.03 | ▼ 0.79% |
| LFUS | Littelfuse, Inc. | USD 456 | ▼ 0.29% |
| CNXN | PC Connection, Inc. | USD 73.28 | ▲ 1.57% |
| FOXF | Fox Factory Holding Corp. | USD 18.13 | ▲ 4.14% |
| NSIT | Insight Enterprises, Inc. | USD 109.8 | ▼ 1.14% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:53 UTC. This page is informational and not investment advice.